# Full refund for CAR-T if the patient has not responded at three months

Source: https://onco.cc/ideas/idea-reg-cart-outcomes-refund/  
OnCo record `idea-reg-cart-outcomes-refund` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Health systems would pay for a $400,000 cell therapy only if it works. If the cancer has not responded by three months, the company refunds the price.

## Summary

Italy's AIFA negotiated payment-by-result for tisagenlecleucel with instalments tied to response, and the US CMS Cell and Gene Therapy Access Model (launched 2025 for sickle cell disease) ties Medicaid payment to outcomes negotiated centrally. The proposal is to make a response-conditional refund the default reimbursement structure for oncology CAR-T and other one-time cell therapies in public systems: full price paid at infusion, automatic full or majority refund if no complete or partial response is documented at 90 days in the treatment registry, with the registry rather than the manufacturer adjudicating.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Response-conditional refunds reduce effective payer spend per durable responder by at least 25% relative to list price and increase the number of centres and countries offering CAR-T, without manufacturers withdrawing from participating markets.
- Rationale: One-time therapies with a binary early response signal are the cleanest case for outcomes-based pricing; the transaction cost problem that defeated earlier schemes is solved when a registry already collects the outcome.
- Proposed test: Extend the CMS CGT Access Model or an equivalent national scheme to relapsed lymphoma and myeloma CAR-T for three years; compare spend per responder and patient volumes with fixed-price countries.
- Maturity: being-tested-at-scale
- Actor: payer

## Sources

- CMS Cell and Gene Therapy Access Model (page moved; nearest live section): https://www.cms.gov/priorities/innovation/innovation-models/

## Connected records

- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- drugs: [Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/), [Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)
- ideas: [Pay for one-time curative therapies as an annuity that stops at relapse](https://onco.cc/ideas/idea-reg-annuity-payment-durable-therapies/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-cart-outcomes-refund.json